CAS 89793-12-4;ethyl 2-chloropyrimidine-5-carboxylate

Nom du produit:ethyl 2-chloropyrimidine-5-carboxylate

IUPAC Name:ethyl 2-chloropyrimidine-5-carboxylate

Unité d'emballage	Stock disponible	Prix($)
CM108980-25g	in stock	ǆƚ
CM108980-100g	in stock	ȋȤǠ
CM108980-500g	in stock	ǺşǺƚ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 89793-12-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:89793-12-4; Formule moléculaire:C7H7ClN2O2; Point de fusion:-; Code SMILES:O=C(C1=CN=C(Cl)N=C1)OCC; Densité:

: Numéro de catalogue:CM108980; Poids moléculaire:186.6; Point d'ébullition:314.2°C at 760 mmHg; N° Mdl:MFCD09863164; Stockage:Keep in a tight container and store at ambient temperature

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Avapritinib; Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.  AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.